By Paul Sankey
Published on April 6, 2024 at 2:38 PM
In this note we consider BP’s position in BPX, its US onshore play, in the context of the overall investment case for BP. Source: BP The following thoughts emerged, embracing multiple metaphors: “A camel is a horse designed by a committee”. BP seems designed by committee. It is a jack of all trades, where it should be the master of one. What is the elevator pitch for buying a stock? BP takes a trans-continental train …
Read More
By Paul Sankey
Published on February 25, 2024 at 7:29 PM
Greetings, There is an embarrassing feeling about current equity markets, for us writing this note, a bit like hosting family lunch on the patio at the country club, while trying to ignore the spectacular naked celebrity gloriously sunbathing by the pool. To be less… conceptual: we got our answer to the question we posed last Sunday on NVDA earnings. ~ It’s hard to avoid staring but we pretend to focus on the slightly dry turkey …
Read More
By Paul Sankey
Published on February 13, 2024 at 8:47 AM
At 6x pro forma EBITDA, FANG should be worth $180-190/share considering $11-12B EBITDA, less purchase-price adjusted net debt and midstream subsidiary Venom (VNOM) non-controlling interest. From there, it is a gravitational pull to $200. Everyone loves round numbers. Like 5,500 on the S&P500. Or Nvidia $1,000. But for oils, we have to rely on fundamental cashflow-based valuation. Source: Company reports, Sankey Research ~ Today’s WSJ feature on Autrey Stephens, the owner of Endeavor Energy, confirms …
Read More
